CEL-SCI Reports Record Monthly Patient Enrollment in April for Its Phase 3 Head and Neck Cancer Trial
CEL-SCI Corporation("CEL SCI" or the "Company") today announced that during the month of April it has enrolled 41 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. This is a new monthly enrollment record, surpassing the prior record of 38 patients enrolled in October 2015. Total patient enrollment for the trial is now 797 as of April 30, 2016.
View full press release